Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anthera's cardiology drug failure leaves analysts ambivalent on remaining SLE product

This article was originally published in Scrip

Executive Summary

The catastrophic termination of Anthera Pharmaceuticals' Phase III programme in cardiovascular disease, which saw the company's share price plummet, has left some analysts undecided on how the one remaining product in its clinical stage pipeline - blisibimod (A-623) for systemic lupus erythematosus – will fare.

Topics

Related Companies

UsernamePublicRestriction

Register

SC016688

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel